Huntingtons Disease Treatment Market To Hit USD 2.5 Billion By 2032, Says Global Market Insights Inc.

(MENAFN- GlobeNewsWire - Nasdaq) Huntingtons disease treatment industry is projected to witness a CAGR of 20.8% during the period 2024-2032. This growth can be attributed to the limited availability of effective treatment.

Selbyville, Delaware, Oct. 10, 2024 (GLOBE NEWSWIRE) --

Huntingtons Disease Treatment market size was valued at USD 457.5 million in 2023, with a projected CAGR of 20.8% over 2024-2032. This growth is fueled by the increasing prevalence of Huntington's disease and significant advancements in medical research.

Request for a sample of this research report @

Improved diagnostic tools and greater awareness have led to the identification of more cases, driving the demand for effective treatments. Advances in genetic testing now enable earlier and more accurate diagnoses, facilitating timely interventions. The availability of generic versions of key medications, such as tetrabenazine, has made treatments more affordable and accessible. Additionally, increased funding and investment from governments, pharmaceutical companies, and private investors, are accelerating the discovery and development of new therapies, further contributing to market expansion.

The overall huntingtons disease treatment market is classified based on the drugs, type, distribution channel, and region.

The market categorizes drugs into tetrabenazine, deutetrabenazine, and other medications. In 2023, tetrabenazine dominated with a 47.8% market share. Tetrabenazine is effective for managing chorea, a major symptom of Huntington's disease, reducing involuntary movements, and improving motor function. Its early regulatory approval and recognition as a specific treatment for Huntington's disease solidifies its market position. Availability in both branded and generic forms provides cost-effective treatment options, maintaining its significant market share.

The huntingtons disease treatment market segments treatments into branded and generic categories. In 2023, the branded segment accounted for USD 258 million, driven by established efficacy and strong brand recognition. Branded medications benefit from comprehensive regulatory approval and frequent endorsements in clinical guidelines, reinforcing their position as standard treatments for various conditions. Extensive marketing campaigns and continued investment in research and development further strengthen the appeal of branded treatments, ensuring they remain at the forefront of medical practice.

In 2023, the North American huntingtons disease treatment market for Huntington's disease treatments was valued at USD 183.9 million, with a projected CAGR of 20.7%. North America has a high prevalence of Huntington's disease, coupled with increased awareness and early diagnostic capabilities. Improved diagnostic tools and awareness campaigns have led to higher diagnosis rates and greater demand for effective treatments. In 2023, the U.S. market for Huntington's disease treatments was valued at USD 167.7 million, projected to reach USD 894.4 million by 2032. The U.S. is a hub for pharmaceutical R&D, with significant investments in developing new therapies for Huntington's disease, supporting growth in the region.

Request for Report Customization @

Major players in huntingtons disease treatment market include Bausch Health Companies Inc., CHEPLAPHARM Arzneimittel GmbH, Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Neurocrine Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC. among others.

Partial Table of Contents (ToC) of the report:

Chapter 1 Methodology & Scope

1.1 Market scope & definitions

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates & calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Increasing prevalence of Huntington's disease

3.2.1.2 Increased research and development activities related to Huntington's disease

3.2.1.3 Growing awareness related to the disease

3.2.2 Industry pitfalls & challenges

3.2.2.1 Limited availability of effective treatment

3.2.2.2 Stringent regulatory requirement

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Pipeline analysis

3.6 Porter's analysis

3.7 PESTEL analysis

Browse more disease specific drugs industry reports @

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

MENAFN10102024004107003653ID1108765381